In addition, while Dasatinib treatment was able to effectively inhibit p‐Lyn and p‐Src expression in HCC cells, the antineoplastic activity of Dasatinib was not correlated to c‐Myc, p‐Lyn, or p‐Src levels. The gene discussed is MYC; the disease is hepatocellular carcinoma.